new england journal of medicine semaglutide In the OASIS 4 phase 3 trial, once-daily oral at a dose 25 mg resulted in a greater mean reduction in body weight than placebo in participants with overweight or The New England... - The

This may affect the intake of essential vitamins and minerals, particularly if the diet becomes more restrictive or less varied

If youre wondering whether you might be a good candidate for Mounjaro or other GLP-1 receptor agonists, this article provides the essential information you need to make an informed decision with your healthcare provider

It works while youre eating and shortly after, but the effects disappear quickly

That's because Mounjaro is a dual GLP-1/GIP (glucose-dependent insulinotropic polypeptide) receptor agonist, which may make it more effective at controlling blood sugar levels and supporting weight loss

& Ahn, J.-M

Others exclude them entirely